A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma

By Varker Kimberly   Biber Jennifer   Kefauver Cheryl   Jensen Rhonda   Lehman Amy   Young Donn   Wu Haifeng   Lesinski Gregory   Kendra Kari   Chen Helen   Walker Michael   Carson III William  

Annals of Surgical Oncology, Vol. 14, Iss. 8, 2007-08 ,pp. : 2367-2376

Springer Publishing Company

Access to resources Recommend Favorite

Metastatic renal cell carcinoma treated with Peg-interferon alfa-2b

By Lyrdal David   Stierner Ulrika   Lundstam Sven  

Acta Oncologica, Vol. 48, Iss. 6, 2009-08 ,pp. : 901-908

Informa Healthcare

Access to resources Recommend Favorite

Failure of Intravesical Interferon-Alfa-2b for the Treatment of Patients with Superficial Bladder Cancer Previously Failing Intravesical BCG Therapy

By Hudson M.A.   Ratliff T.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 1, Iss. 3, 1995-05 ,pp. : 115-118

Elsevier

Access to resources Recommend Favorite

Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma

By Lafuma A.   Dreno B.   Delaunay M.   Emery C.   Fagnani F.   Hieke K.   Bonerandi J.-J.   Grob J.-J.   for the French Cooperative Group on Melanoma  

European Journal of Cancer, Vol. 37, Iss. 3, 2001-02 ,pp. : 369-375

Elsevier

Access to resources Recommend Favorite

Systemic therapy of malignant melanoma

By Hansson Johan  

Medical Oncology, Vol. 14, Iss. 2, 1997-06 ,pp. : 73-81

Humana Press, Inc

Access to resources Recommend Favorite